| abstract |
REFERS TO A SPIROPIPERIDINE COMPOUNDS WHERE R1 IS H, C1-C6 ALKYL DON HALO, OH, CARBOXI, AMONG OTHERS. TWO R1 GROUPS TAKEN TOGETHER FORM -CH2-, - (CH2) 2-; R2 IS H, HALO, HYDROXY, C1-C6 ALKYL WITH HALO, OH, CARBOXY, AMONG OTHERS; X1 AND X2 ARE (CH2) n1 WHERE n1 IS FROM 1-3, C [(C1-C6) ALKYL], C-OH, O, NH, AMONG OTHERS; X1 AND X2 TOGETHER FORM CH = CH; W1 AND W2 ARE CRw1Rw2 BEING Rw1 AND Rw2 H, HALO, HYDROXY, C1-C6 ALKYL, AMONG OTHERS; A IS GROUP AA AMONG OTHERS; IT IS ALREADY SELECTED AMONG (CH2) n2 WHERE N2 IS A NUMBER AMONG 0-2, C (= O), NH, AMONG OTHERS; Z IS C (= O), (CH2) n8 BEING n8 FROM 0-2. THE PREFERRED COMPOUNDS ARE 2,3-DIHYDRO-1 '- [3- (2-METOXICARBONYLINDOLIN-1-IL) -3-OXOPROPYL] SPIRO [1H-INDENO-1,4'-PIPERIDINE HYDROCHLORIDE] -DIHYDRO-1 '- [3- (INDOLIN-1-IL) -3-OXOPROPYL] SPYRO [1H-INDENO-1,4'-PIPERIDINE], AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THE MENTIONED COMPOUNDS ARE BINDING TO THE ENT-1 RECEPTOR AND ARE USEFUL FOR THE TREATMENT OF CNS DISORDERS |